MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Intercept Pharmaceuticals Company Profile (NASDAQ:ICPT)

Consensus Ratings for Intercept Pharmaceuticals (NASDAQ:ICPT) (?)
Ratings Breakdown: 2 Sell Rating(s), 4 Hold Rating(s), 13 Buy Rating(s)
Consensus Rating:Buy (Score: 2.58)
Consensus Price Target: $212.47 (50.46% upside)

Analysts' Ratings History for Intercept Pharmaceuticals (NASDAQ:ICPT)
Show:
DateFirmActionRatingPrice TargetActions
5/20/2016Needham & Company LLCReiterated RatingBuy$350.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/10/2016OppenheimerReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/9/2016FBR & Co.UpgradeMarketperform -> OutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/10/2016Credit SuisseReiterated RatingBuy$200.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/8/2016Morgan StanleyReiterated RatingSellView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/8/2016Robert W. BairdReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/6/2016WedbushReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/6/2016Cowen and CompanyReiterated RatingBuy$212.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/3/2016BMO Capital MarketsReiterated RatingBuy$239.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/3/2016Wells FargoReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/9/2016Bank of AmericaReiterated RatingSell$144.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/6/2016Leerink SwannReiterated RatingHold$144.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/30/2016JMP SecuritiesReiterated RatingBuy$200.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/30/2016Goldman SachsInitiated CoverageBuy -> Neutral$114.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/24/2016BarclaysLower Price TargetOverweight$300.00 -> $200.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/28/2016S&P Equity ResearchReiterated RatingAverage$100.60 -> $111.91View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/7/2015Janney Montgomery ScottReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/24/2015RBC CapitalReiterated RatingOutperform$490.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/1/2015MLV & Co.Reiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/27/2015Deutsche BankBoost Price TargetBuy$300.00 -> $400.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/20/2015NomuraSet Price TargetBuy$440.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/18/2014Sterne Agee CRTInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/4/2014Summer StreetReiterated RatingPositiveView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 5/25/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha